Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, will present at the H.C. Wainwright Global Investment Conference from September 12-14, 2022. Investors can participate in virtual and in-person meetings in New York, NY. Reviva focuses on developing therapies for unmet medical needs, particularly in the central nervous system, cardiovascular, metabolic, and inflammatory diseases. The company’s pipeline includes drug candidates RP5063 and RP1208, both of which have received patent protections.
- None.
- None.
CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held September 12–14, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in New York, NY. Please see additional details below:
H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
| Date: | Wednesday, September 14th |
| Time: | 12:30 p.m. ET |
| Speaker: | Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals |
| Format: | Company Presentation |
Please contact your representative at H.C. Wainwright to schedule an in-person or virtual one-on-one meeting with Reviva Pharmaceuticals during the respective conference.
For information about the H.C. Wainwright Global Investment Conference, please refer to the events website.
About Reviva
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals presenting at the H.C. Wainwright Global Investment Conference?
Who is the CEO of Reviva Pharmaceuticals?
What is the focus of Reviva Pharmaceuticals' drug development?
What are the key drug candidates in Reviva's pipeline?
Where can I find more details about the H.C. Wainwright Global Investment Conference?
